Unexpectedly, Belimumab did not demonstrate significant efficacy in a phase II clinical trial for Myasthenia Gravis (AChR and MuSK) (ClinicalTrials.gov Identifier: NCT01480596) (256). The gene discussed is MUSK; the disease is myasthenia gravis.